Glucose News and Research

RSS

No amount of added sugar is right

According to a recently released study that traced the eating habits of Minnesota residents for 27 years, the body weight of Americans is rising along with their increased intake of sugars added to processed and home-cooked foods.

31 Mar 2011

Study provides insight into kidney cancer

Researchers at UT Southwestern Medical Center have discovered genetic pathways to starve selectively kidney cancer cells.

31 Mar 2011

Non-invasive blood glucose monitor closer to market

People with diabetes could soon have a pain-free way to check their blood glucose levels. Researchers at the University of Missouri–St. Louis have developed a portable, inexpensive non-invasive blood glucose detector. The university has licensed patent rights for the device to St. Louis Medical Devices, Inc., a Missouri company headquartered at UMSL’s own startup company incubator – IT Enterprises, to bring the device to market.

30 Mar 2011

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011

Pathfinder cell-based therapy reverses diabetes in mouse model

Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model.

30 Mar 2011

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.

30 Mar 2011

McKesson awards GW with two grants to study mobile-phone use in diabetic patients

GW researchers have been awarded two grants from the McKesson Foundation as part of its Mobilizing for Health initiative, an initiative to improve the health of underserved populations with chronic diseases through the use of mobile-phone technology.

29 Mar 2011

IDF: Obese people with type 2 diabetes can benefit from bariatric surgery

Bariatric surgery should be considered earlier in the treatment of eligible patients to help stem the serious complications that can result from diabetes, according to an International Diabetes Federation position statement presented by leading experts at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes in New York.

29 Mar 2011

Researchers find patients with Alzheimer's have lower glucose utilization in brain

Researchers at Mount Sinai School of Medicine have found that patients with Alzheimer's disease have lower glucose utilization in the brain than those with normal cognitive function, and that those decreased levels may be detectable approximately 20 years prior to the first symptoms of Alzheimer's disease.

29 Mar 2011

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

ActiveSite Pharmaceuticals, Inc., announced today the online publication of a study in the journal Diabetes that describes the effectiveness of its novel plasma kallikrein inhibitor ASP-440 in reducing blood-retinal barrier breakdown in a rodent model of diabetes.

28 Mar 2011

Diabetic smokers beware - Nicotine raises blood sugar: Study

U.S. researchers have found that nicotine in cigarettes may be responsible for serious complications in smokers with diabetes. They have shown that nicotine is strongly linked to persistently raised blood sugar levels among diabetics and scientists say they should make every effort to quit. There may also be implications for diabetics attempting to give up the habit who use nicotine-replacement therapy for extended periods.

27 Mar 2011

Scientists discover hormone pathway that can lead to new diabetes treatment

Researchers at UT Southwestern Medical Center have discovered a hormone pathway that potentially could lead to new ways of treating type 1 diabetes independent of insulin, long thought to be the sole regulator of carbohydrates in the liver.

25 Mar 2011

Sitagliptin drug can slow onset of diabetes

Diabetes type 2 is caused by insufficient levels of insulin to keep blood glucose under control. Excessive levels of another hormone, glucagon, can also contribute to diabetes type 2 by causing the liver to flood the body with stored glucose.

25 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

Collaborative study may lead to strategies to reduce antibiotic resistance

In a study that literally analyzed competing bacteria fighting it out to the death, a University of Houston (UH) researcher and his colleagues identified evolutionary 'winners' and 'losers.' Continuing research to understand the basis of these fates may become a useful tool is designing roadblocks to antibiotic resistance.

24 Mar 2011

Daily dose of safflower oil can help reduce cardiovascular disease

A daily dose of safflower oil, a common cooking oil, for 16 weeks can improve such health measures as good cholesterol, blood sugar, insulin sensitivity and inflammation in obese postmenopausal women who have Type 2 diabetes, according to new research.

22 Mar 2011

City Of Hope opens new center for diabetes research and care

City of Hope has established a new Diabetes Research Center that will expand its pioneering investigations into diabetes, endocrinology and metabolic diseases, create an infrastructure to support translational research and enhance clinical care for diabetes and its related complications.

22 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Echo Therapeutics fiscal 2010 net loss decreases to $4.1 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the year ended December 31, 2010.

21 Mar 2011

Elevations in 5 amino acids may signal future disease risk

Measuring the levels of small molecules in the blood may be able to identify individuals at elevated risk of developing type 2 diabetes as much as a decade before symptoms of the disorder appear.

21 Mar 2011